

ANTIRETROVIRAL THERAPY FOR HIV INFECTION IN INFANTS AND CHILDREN: TOWARDS UNIVERSAL ACCESS

Recommendations for a public health approach

2010 revision



World Health
Organization

WHO Library Cataloguing-in-Publication Data

Antiretroviral therapy of HIV infection in infants and children: towards universal access: recommendations for a public health approach - 2010 revision.

1. Anti-retroviral agents - therapeutic use. 2. Anti-retroviral agents - pharmacology. 3. Antiretroviral therapy, Highly active. 4. HIV infections – drug therapy. 5. Infant. 6. Child. 7. Adolescent. 8. Guidelines. 9. Developing countries. I. World Health Organization.

ISBN 978 92 4 159980 1

(NLM classification: WC 503.2)

© World Health Organization 2010

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed in Austria

ANTIRETROVIRAL THERAPY FOR HIV INFECTION IN INFANTS AND CHILDREN: TOWARDS UNIVERSAL ACCESS

Recommendations
for a public health approach

2010 revision



**World Health
Organization**



CONTENTS

Acronyms and abbreviations	vi
Executive summary	1
1. Introduction.....	8
2. Objectives of the Guidelines.....	9
3. Development of the Guidelines	10
4. Establishing a diagnosis of HIV infection in infants and children	14
5. When to start antiretroviral therapy in infants and children.....	22
6. What to start? recommended first-line ARV regimens for infants and children.....	28
7. Clinical and laboratory monitoring.....	38
8. What to expect in the first six months of therapy	43
9. ARV drug toxicity	45
10. Substituting drugs because of toxicity in infants and children.....	48
11. First-line regimen treatment failure: when to switch regimens.....	50
12. Choice of second-line regimens in the event of treatment failure	55
13. Considerations for infants and children with tuberculosis and HIV.....	59
14. Nutrition for HIV-infected infants and children.....	69
15. Considerations for ART in adolescents	76
16. Adherence to ART.....	78
17. Strategies in the event of failure of second-line regimens	81
18. Drug resistance.....	83
 Annex A: Members of the technical reference group on paediatric HIV care and treatment.....	87
Annex B: Grading of recommendations and levels of evidence	90
Annex C: WHO clinical staging of HIV for infants and children with established HIV infection ...	93
Annex D: Presumptive and definitive criteria for recognizing HIV-related clinical events in infants and children with established HIV infection.....	95
Annex E: Prescribing information and weight-based dosing of available ARV formulations for infants and children.....	100
Annex F: Serious, acute and chronic toxicities caused by ARV drugs.....	154
Annex G: Severity grading of selected clinical and laboratory toxicities most commonly seen with recommended antiretroviral drugs for children	158
Annex H: Sexual maturity rating (Tanner staging) in adolescents.....	162
Annex I: Summary of WHO recommendations on laboratory investigations for clinical care by level of health care facility.....	164
Annex J: Figures.....	168
Annex K: References	181

TABLES

Table 1: GRADE approach to ranking the quality of a body of evidence	12
Table 2: Assessment of the strength of a recommendation	12
Table 3: Summary of testing methods for infants and children	20
Table 4: Explanation of age terminology used in these recommendations	22
Table 5: WHO classification of HIV-associated clinical disease	24
Table 6: Recommendations for initiating ART in infants and children: revised in 2010	25
Table 7: Recommendations for initiating ART in HIV-infected infants and children according to clinical stage and immunological markers	26
Table 8: Criteria for presumptive diagnosis of severe HIV disease in infants and children aged less than 18 months where viral testing is not available	28
Table 9: Examples of NRTIs and NNRTIs	29
Table 10: Summary of preferred first-line ARV regimens for infants and children	36
Table 11: Preferred first-line regimens for specific situations	37
Table 12: Laboratory parameters for monitoring infants and children at baseline, before and during ART	41
Table 13: Severe toxicities of first-line ARVs in infants and children, and potential drug substitutions	49
Table 14: Using WHO paediatric clinical staging of events to guide decision-making on switching to second-line therapy for treatment failure	51
Table 15: Decision-making on switching to second-line therapy for treatment failure based on availability of CD4 measurement	53
Table 16: Preferred first- and second-line regimens	58
Table 17: Recommended second-line regimens in infants and children in the event of treatment failure of first-line regimens	58
Table 18: Simplified, weight-based dosing for isoniazid 10 mg/kg/day	61
Table 19: Recommendations for the timing of ART following the initiation of TB treatment with a rifampicin-containing regimen in HIV-infected infants and children	66
Table 20: Recommendations for co-management of TB and HIV in infants and children diagnosed with TB while on ART	67
Table 21: Proposed clinical case definition of paradoxical TB-associated IRIS	68
Table 22: Definitions of nutritional terms	71
Table 23: WHO HIV drug resistance early warning indicators	85

BOXES

Box 1: Standard regimen for first-line ART.....	29
Box 2: Preferred regimen for NVP-naïve infants or children <24 months with no known prior exposure to NVP.....	31
Box 3: Preferred initial regimen for NNRTI-exposed infants or children <24 months.....	32
Box 4: Recommended alternative ART regimen for infants and children to simplify management of toxicity, comorbidity and drug – drug interaction	32
Box 5: Nevirapine-based regimens.....	37
Box 6: Efavirenz-based regimens	37
Box 7: Protease inhibitor-based regimens	37
Box 8: Baseline clinical assessment for children	39
Box 9: Baseline laboratory assessment for children	40
Box 10: Guiding principles for the management of ARV drug toxicity.....	47
Box 11: CD4 criteria suggesting immunological failure	52
Box 12: Preferred ARV regimens for TB/HIV coinfecting infants and children less than 3 years of age	62
Box 13: Preferred ART regimens for TB/HIV coinfecting children 3 years of age or more.....	63
Box 14: Examples of palliative care support and programmes	82

ACRONYMS AND ABBREVIATIONS

3TC	lamivudine	DMPA	depot medroxyprogesterone acetate
ABC	abacavir	DNA	deoxyribonucleic acid
AFB	acid-fast bacilli	DOT	directly observed therapy
AIDS	acquired immunodeficiency syndrome	EC	enteric-coated
ALT	alanine aminotransferase	EFV	efavirenz
a.m.	ante meridiem (denotes morning)	EIA	enzyme immunoassay
ANC	antenatal care	EML	Essential Medicines List
ART	antiretroviral therapy	ELISA	enzyme-linked immunosorbent assay
ARV	antiretroviral (drug)	ETV	etravirine
AST	aspartate aminotransferase	EU	European Union
ATV	atazanavir	EWI	early warning indicator
AUC	area under curve	FDC	fixed-dose combination
AZT	zidovudine (also known as ZDV)	FDC	fixed-dose combination
BAL	bronchoalveolar lavage	FPV	fos-amprénavir
BCG	bacille Calmette – Guérin (vaccine)	FTC	emtricitabine
BSA	body surface area	Grade	grading of recommendations assessment, development and evaluation
CD4+	T-lymphocyte bearing CD4 receptor	HAART	highly active antiretroviral therapy
%CD4+	percent CD4+	HDL	high-density lipoprotein
CDC	Centers for Disease Control and Prevention	Hgb	haemoglobin
CHAP	Children with HIV Antibody Prophylaxis (clinical trial)	HGC	hard gel capsule
		HIV	human immunodeficiency virus
		HIVDR	HIV drug resistance

预览已结束，完整报告链接和

<https://www.yunbaogao.cn/report/index/report>